Agios Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$58.6M
Doctors Paid
5,070
Transactions
17,786
2024 Total
$6.1M
Payment Breakdown by Category
Research$49.0M (83.6%)
Consulting$3.2M (5.4%)
Travel$361,242 (0.6%)
Food & Beverage$286,069 (0.5%)
Royalty/License$213,380 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $49.0M | 5,514 | 83.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.3M | 97 | 5.6% |
| Consulting Fee | $3.2M | 683 | 5.4% |
| Honoraria | $1.4M | 669 | 2.3% |
| Grant | $580,250 | 10 | 1.0% |
| Travel and Lodging | $361,242 | 1,233 | 0.6% |
| Food and Beverage | $286,069 | 9,123 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $230,599 | 83 | 0.4% |
| Royalty or License | $213,380 | 10 | 0.4% |
| Education | $134,233 | 362 | 0.2% |
| Charitable Contribution | $11,500 | 2 | 0.0% |
Payments by Type
Research
$49.0M
5,514 transactions
General
$9.6M
12,272 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Sponsored Research Agreement | $2.6M | 1 | 53 |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vorasidenib in Subjects with Recurrent, Non-enhancing, Low-grade Glioma with an IDH1 or IDH2 Mutation | $2.2M | 0 | 326 |
| A PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA | $2.1M | 0 | 109 |
| Investigator Sponsored Trial | $2.0M | 2 | 35 |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 andor IDH2 Mutation | $1.7M | 0 | 77 |
| A Phase I, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 andor IDH2 Mutation | $1.7M | 0 | 81 |
| Beat AML Study | $1.7M | 0 | 5 |
| AG270-C-001 | $1.6M | 0 | 113 |
| AG348-C-011 | $1.6M | 0 | 250 |
| AG348-C-006 | $1.5M | 0 | 133 |
| Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations ClarIDHy | $1.5M | 0 | 271 |
| A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease | $1.5M | 6 | 327 |
| A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | $1.4M | 0 | 114 |
| STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY | $1.4M | 0 | 390 |
| AG881-C-005 | $1.4M | 0 | 7 |
| AG348-C-019 | $1.3M | 0 | 9 |
| STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | $1.3M | 0 | 117 |
| AG348-C-023 | $1.1M | 0 | 192 |
| AG348-C-018 | $1.1M | 0 | 137 |
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation | $1.0M | 0 | 288 |
| NCT02632708 | $981,389 | 0 | 57 |
| A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | $979,709 | 0 | 214 |
| STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES WITH AN IDH1 MUTATION | $956,453 | 0 | 141 |
| AG348-C-022 | $948,960 | 0 | 185 |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | $937,735 | 0 | 53 |
| A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects with Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma | $926,623 | 0 | 140 |
| A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 andor IDH2 Mutation | $730,018 | 0 | 144 |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | $714,130 | 0 | 32 |
| A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Subjects with Sickle Cell Disease | $713,858 | 0 | 171 |
| AG348-C-010 | $700,013 | 0 | 60 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. David Scadden, Md, MD | Internal Medicine | Boston, MA | $2.2M | $0 |
| David Schenkein, Md, MD | Internal Medicine | Boston, MA | $1.4M | $0 |
| Dr. Matthew Vanderheiden, Md Phd, MD PHD | Hematology & Oncology | Boston, MA | $312,000 | $0 |
| Dr. Gilad Gordon, Md, MD | Internal Medicine | Boulder, CO | $291,781 | $0 |
| Angela Acha, Fnp-C, FNP-C | Family | Pflugerville, TX | $173,625 | $0 |
| Rachael Grace, Md, MD | Pediatrics | Boston, MA | $139,658 | $0 |
| Dr. Sujit Sheth | Pediatric Hematology-Oncology | New York, NY | $109,338 | $0 |
| Hanny Al-Samkari, Md, MD | Hematology & Oncology | Boston, MA | $103,891 | $0 |
| Caterina Minniti, Md, MD | Pediatric Hematology-Oncology | Washington, DC | $99,073 | $0 |
| Harry Erba, Md, MD | Internal Medicine | Ann Arbor, MI | $92,555 | $0 |
| Craig Thompson, Md, MD | Medical Oncology | New York, NY | $81,750 | $0 |
| Dr. Thomas Leblanc, Md, Ma, MD, MA | Medical Oncology | Durham, NC | $81,536 | $0 |
| Susan Perrine, Md, MD | Hematology & Oncology | Boston, MA | $79,715 | $0 |
| Nirmish Shah, Md, MD | Internal Medicine | Durham, NC | $78,333 | $0 |
| Dr. Steven Fein, M.d, M.D | Hematology & Oncology | Miami, FL | $59,627 | $0 |
| Hetty Carraway, M.d, M.D | Hematology & Oncology | Chagrin Falls, OH | $59,064 | $0 |
| Dr. Ralph Deberardinis, Md Phd, MD PHD | Clinical Genetics (M.D.) | Dallas, TX | $56,380 | $0 |
| Gail Roboz, Md, MD | Internal Medicine | New York, NY | $54,838 | $0 |
| Sandra Richman, M.d, M.D | Internal Medicine | Brookline, MA | $53,125 | $0 |
| Biree Andemariam, Md, MD | Hematology & Oncology | Farmington, CT | $51,860 | $0 |
| Bertil Glader, Md, MD | Pediatric Hematology-Oncology | Palo Alto, CA | $45,863 | $0 |
| Sherif Badawy, Md, MD | Pediatric Hematology-Oncology | Chicago, IL | $44,311 | $0 |
| Michael Bishop | Hematology & Oncology | Chicago, IL | $42,423 | $0 |
| Dr. Florence Houn, Md, MD | Internal Medicine | Potomac, MD | $42,079 | $0 |
| Charles Sawyers, M.d, M.D | Hematology & Oncology | New York, NY | $40,386 | $0 |
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. has made $58.6M in payments to 5,070 healthcare providers, recorded across 17,786 transactions in the CMS Open Payments database. In 2024, the company paid $6.1M. The top product by payment volume is TIBSOVO ($18.6M).
Payments were distributed across 108 medical specialties. The top specialty by payment amount is Internal Medicine ($4.7M to 605 doctors).
Payment categories include: Food & Beverage ($286,069), Consulting ($3.2M), Research ($49.0M), Travel & Lodging ($361,242), Royalties ($213,380).
Agios Pharmaceuticals, Inc. is associated with 2 products in the CMS Open Payments database.